March 15, 2013
Eli Lilly Japan has filed a New Drug Application (NDA) for the phosphodiesterase type 5 inhibitor tadalafil, which is currently marketed as the erectile dysfunction (ED) drug Cialis and the pulmonary arterial hypertension (PAH) treatment Adcirca, for an expected indication...read more